Patient living with advanced lung cancer

Jodi Parker, a cancer advocate and patient living with advanced lung cancer shares her journey and her involvement with Merck’s and the GO2 Foundation for Lung Cancer’s new patient awareness initiative “Worth the Fight: Taking on Lung Cancer” that offers support and resources to people impacted by advanced lung cancer and empowers them to take an active role in their cancer care.

Read More

Neurotrophic Tropomyosin Receptor Kinase (NTRK) gene fusions

Dr. Marcia Brose, Associate Professor at the University of Pennsylvania School of Medicine discusses the role of cancer genomic testing and Neurotrophic Tropomyosin Receptor Kinase (NTRK) gene fusions.  NTRK gene fusions can cause cancer cells to multiply, form tumors, and are more common in certain thyroid and colon cancer subtypes.  Bayer and Neogenomics Inc. launched the Test4TRK™ program to offer genomic cancer testing for NTRK gene fusions at no cost for patients who meet certain criteria. 

Read More

Eleusis Therapeutics & Health Solutions – Psychedelic Medicine

Eleusis is a clinical-stage life science company that has two lines of business:  a traditional drug development arm called Eleusis Therapeutics, and a care delivery platform called Eleusis Health Solutions.  Here to discuss the company and the potential and power of psychedelic medicine in treating chronic inflammatory disease, mental health, and Alzheimer’s is CEO, founder, and chairman, Shlomi Raz.

Read More

Women’s Heart Health

Dr. Suzanne Steinbaum, a cardiologist, discusses the controversy between women and statins, best practices on how women with a full plate of responsibilities can still prioritize their health, and how she maintains open relationships with her patients in this new virtual landscape.

Read More

Capricor’s CAP-1002 – COVID-19 survival of critical patients

Dr. Linda Marbán, President, CEO and Director of Capricor Therapeutics discusses new data reporting 100 percent survival in critical COVID-19 patients that were treated with her team’s off-the-shelf, cardiac cell therapy CAP-1002. These patients were part of six compassionate care cases treated at Cedars-Sinai Medical Center in Los Angeles, and following a review of the data, the FDA approved the company’s expanded access protocol to treat additional COVID-19 patients with this novel new therapeutic.

Read More